Michael E. Lamb*, MSFS, D-ABFT-FT
Donna M. Papsun, MS, D-ABFT-FT
Ayako Chan Hosokawa, MS, D-ABFT-FT

Impact statement

This poster provides a review of changes in prevalence of specific designer benzodiazepines (DBZD) in impaired driving casework submitted to NMS Labs between 2017 and 2021, as well as the overall increase in detected DBZD in the same time period. It is noted that DBZD use may be underreported due to variable scopes of analytical testing and recommends investigation be performed on unconfirmed benzodiazepine immunoassay screens due to DBZD high cross-reactivity with commercial products. Further, cases in which a DBZD was the sole drug reported or primary drug of interest in the investigation were selected for further discussion.

Request a Copy

Request a PDF copy of the poster by completing the information below.

Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.